Allelotypes as potential prognostic markers in ovarian carcinoma treated with cisplatin-based chemotherapy

  • Authors:
    • Satoru Nakayama
    • Kentaro Nakayama
    • Yuji Takebayashi
    • Kohkichi Hata
    • Ritsuto Fujiwaki
    • Manabu Fukumoto
    • Kohji Miyazaki
  • View Affiliations

  • Published online on: May 1, 2003     https://doi.org/10.3892/ijmm.11.5.621
  • Pages: 621-625
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We analyzed a series of ovarian carcinomas from patients treated with cisplatin-based chemotherapy for loss of heterozygosity (LOH) to determine the relationship between microsatellite alteration and prognosis. Patients with tumors that had lost alleles at loci 3p14-21, 12qter, or 17p13.3 showed significantly reduced survival compared to patients with tumors that retained both alleles at those loci. The 5-year mortality rates for patients exhibiting allele loss and patients with allele retention were 50 and 41%, respectively, for the 3p14-21 locus (P=0.0023); 57 and 24%, respectively, for 12qter (P=0.0256); and 55 and 40%, respectively, for 17p13.3 (P=0.0489). A statistically significant difference was also observed with respect to fractional allelic loss (FAL), which was a significant indicator for disease recurrence (P=0.0227). The prognosis of patients with high FAL values were significantly worse compared to those with low FAL values (P=0.0306). Our results suggested that LOH at loci 3p14-21, 12qter, or 17p13.3 was a significant predictor of poor survival in ovarian carcinomas treated with cisplatin-based chemotherapy. Furthermore, the association of FAL value with therapy response indicated that ovarian carcinomas with high levels of chromosomal alteration may be more resistant to this type of chemotherapy.

Related Articles

Journal Cover

May 2003
Volume 11 Issue 5

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Nakayama S, Nakayama K, Takebayashi Y, Hata K, Fujiwaki R, Fukumoto M and Miyazaki K: Allelotypes as potential prognostic markers in ovarian carcinoma treated with cisplatin-based chemotherapy. Int J Mol Med 11: 621-625, 2003
APA
Nakayama, S., Nakayama, K., Takebayashi, Y., Hata, K., Fujiwaki, R., Fukumoto, M., & Miyazaki, K. (2003). Allelotypes as potential prognostic markers in ovarian carcinoma treated with cisplatin-based chemotherapy. International Journal of Molecular Medicine, 11, 621-625. https://doi.org/10.3892/ijmm.11.5.621
MLA
Nakayama, S., Nakayama, K., Takebayashi, Y., Hata, K., Fujiwaki, R., Fukumoto, M., Miyazaki, K."Allelotypes as potential prognostic markers in ovarian carcinoma treated with cisplatin-based chemotherapy". International Journal of Molecular Medicine 11.5 (2003): 621-625.
Chicago
Nakayama, S., Nakayama, K., Takebayashi, Y., Hata, K., Fujiwaki, R., Fukumoto, M., Miyazaki, K."Allelotypes as potential prognostic markers in ovarian carcinoma treated with cisplatin-based chemotherapy". International Journal of Molecular Medicine 11, no. 5 (2003): 621-625. https://doi.org/10.3892/ijmm.11.5.621